LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris

See also
Status	Clinical Trial	Phase
Completed	`NCT03669757` - Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis	Phase 1
Completed	`NCT03614078` - A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis	Phase 2
Completed	`NCT03584360` - Role of Topical Treatments in the Modulation of Skin Microbiome in Psoriatic Skin	Phase 2
Recruiting	`NCT04994951` - Pilot Study of Traditional Chinese Medicine (Qing-Re-Liang-Xue Decoction) as Complementary Medicine for Psoriasis Vulgaris of Blood-heat Syndrome.	Phase 2
Completed	`NCT02888236` - LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris	Phase 2
Completed	`NCT02533973` - Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population	Phase 4
Completed	`NCT02193815` - A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis	Phase 1
Completed	`NCT01946386` - A Vasoconstriction Study With LEO 90100	Phase 1
Completed	`NCT02004847` - Blue Light for Treating Psoriasis Vulgaris	N/A
Recruiting	`NCT01443338` - Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2	Phase 4
Completed	`NCT01188928` - LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)	Phase 3
Completed	`NCT00764751` - Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris	Phase 2
Completed	`NCT00236171` - Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test	N/A
Completed	`NCT04541329` - Predicting Inflammatory Skin Disease Response to IL-23 Blockade	Phase 4
Completed	`NCT06064084` - Incretin Effect in Patients With Psoriasis and Controls
Not yet recruiting	`NCT06398106` - Proactive TDM Versus Standard Use of Biologics in Psoriasis	Phase 4
Recruiting	`NCT05892640` - Low-Salt Diet Effect on Th17-Mediated Inflammation and Vascular Reactivity in Psoriasis	N/A
Recruiting	`NCT05390515` - Psoriatic Immune Response to Tildrakizumab	Phase 4
Recruiting	`NCT04950218` - The Psoriasis Echo Study
Completed	`NCT05184348` - Plexin B2 Gene Expression and Polymorphisms in Psoriasis	Phase 1

NCT number	NCT01866163
Study type	Interventional
Source	LEO Pharma
Contact
Status	Completed
Phase	Phase 3
Start date	June 2013
Completion date	November 2013

LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms